Fosamax Plus patent doesn't belong to patent scope of Maxmarvil, Intellectual Property Tribunal says

Published: 2007-11-21 06:59:00
Updated: 2007-11-21 06:59:00
The Korea Intellectual Property Tribunal rejected Yuyu Pharm's request to confirm whether MSD Korea's Fosamax Plus (70 mg alendronate/5,600 IU vitamin D3) is not in the patent scope of Yuyu's Maxmarvil (Korean Patent No. 317935).

The tribunal said in its ruling on June 5, 2006 that Yuyu's pate...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.